Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19512291 | 0.80 | KMT2A (0.39) | KDM4EPKMKMT2A | |
| SCHEMBL25763073 | 0.80 | KMT2A (0.39) | KDM4EPKMKMT2A | |
| SCHEMBL20899705 | 0.78 | KMT2A (0.38) | KDM4EPKMKMT2A | |
| SCHEMBL4577529 | 0.78 | KMT2A (0.38) | KDM4EPKMKMT2AHIF1A | |
| SCHEMBL2857868 | 0.78 | — | — | |
| SCHEMBL9913289 | 0.78 | KDM4E (0.39) | KDM4EPKMKMT2AEPHX1THRB | |
| SCHEMBL14902212 | 0.77 | KMT2A (0.35) | KDM4EPKMKMT2AHTT | |
| SCHEMBL13016481 | 0.76 | KMT2A (0.37) | PKMKMT2A | |
| SCHEMBL13890770 | 0.76 | KMT2A (0.37) | KMT2A | |
| SCHEMBL15789667 | 0.76 | KMT2A (0.37) | KMT2ACA2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602759-B | Method for preparing a composition of alkanolamine alkylamide and polyol | 阿克苏诺贝尔化学品国际有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3545009-B1 | PHOTOINITATORS | COLOPLAST AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| US-10266486-B2 | Method of making a composition of an alkanolamine alkylamide and a polyol | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2019-04-23 | — | — | US | disclosed |
| US-20190031598-A1 | METHOD OF MAKING A COMPOSITION OF AN ALKANOLAMINE ALKYLAMIDE AND A POLYOL | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2019-01-31 | — | — | US | disclosed |
| EP-2863916-B1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2018-07-18 | — | — | EP | disclosed |
| WO-2018095495-A1 | PHOTOINITATORS | COLOPLAST A/S (DK) | 2018-05-31 | — | — | WO | disclosed |
| EP-3091011-B1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2017129272-A1 | METHOD OF MAKING A COMPOSITION OF AN ALKANOLAMINE ALKYLAMIDE AND A POLYOL | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2017-08-03 | — | — | WO | disclosed |
| US-20170189389-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-06 | — | — | US | disclosed |
| US-20160271105-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-09-22 | — | — | US | disclosed |
| US-8912199-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140080826-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140057906-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140038941-A1 | RING-FUSED HETEROCYCLIC DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-02-06 | — | — | US | disclosed |
| US-20140038941-A1 | RING-FUSED HETEROCYCLIC DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-02-06 | — | — | US | disclosed |
| US-8623905-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-07 | — | — | US | disclosed |
| US-8575209-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| EP-1255751-B1 | 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND THEIR USE AS LIGANDS FOR V1B OR V1B AND V1A ARGININE-VASOPRESSIN RECEPTORS | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031598-A1 | METHOD OF MAKING A COMPOSITION OF AN ALKANOLAMINE ALKYLAMIDE AND A POLYOL | PHOSPHO1, SGMS2, SGMS1 | KDM4E 3170/4885PKM 1427/4885KMT2A 691/4885 |
| US-20140080826-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885PKM 3330/4885KMT2A 4313/4885 |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | KDM4E 4481/4885PKM 2352/4885KMT2A 4359/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | KDM4E 4481/4885PKM 2352/4885KMT2A 4359/4885 |
| US-20140057906-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885PKM 3330/4885KMT2A 4313/4885 |
| US-20170189389-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885PKM 3330/4885KMT2A 4313/4885 |
| US-20140038941-A1 | RING-FUSED HETEROCYCLIC DERIVATIVE | CACNA1E, SLC8A1, CALCR | KDM4E 3779/4885PKM 4852/4885KMT2A 3414/4885 |
| US-20160271105-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885PKM 3330/4885KMT2A 4313/4885 |
| US-10266486-B2 | Method of making a composition of an alkanolamine alkylamide and a polyol | PHOSPHO1, SGMS2, SGMS1 | KDM4E 3170/4885PKM 1427/4885KMT2A 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.